搜索临床试验以:聚IC-LC
总计1594个结果
-
Allarity TherapeuticsDanish Breast Cancer Cooperative Group; Smerud Medical Research International AS主动,不招人
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZeneca主动,不招人转移性乳腺癌 | 浸润性乳腺癌 | BRIP1基因突变 | PALB2基因突变 | ATM基因突变 | CHEK2基因突变 | NBN基因突变 | RAD51基因突变 | 体细胞突变乳腺癌 (BRCA1) | 体细胞突变乳腺癌 (BRCA2)美国
-
AstraZenecaKuDOS Pharmaceuticals Limited完全的
-
Brown UniversityAstraZeneca; The Miriam Hospital; Rhode Island Hospital终止
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United Kingdom完全的
-
Paul Mathew, MDHoosier Cancer Research Network; Tesaro, Inc.终止
-
PfizerMedivation, Inc.完全的急性髓性白血病 | 套细胞淋巴瘤 | 慢性淋巴细胞白血病 | 骨髓增生异常综合症英国, 美国
-
Nova Scotia Health Authority终止
-
VA Office of Research and DevelopmentOncovir, Inc.尚未招聘
-
AstraZeneca主动,不招人
-
Haihe Biopharma Co., Ltd.终止
-
GlaxoSmithKline暂停
-
Arcagy ResearchBelgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer de Ovario; Multicenter... 和其他合作者完全的
-
AbbVie不再可用高级别浆液性卵巢癌 | 具有记录在案的 BRCA、BARD 或 PALB 或其他科学上合理的可接受的 DNA 突变或异常的实体瘤 | 三阴性乳腺癌 (TNBC) | 需要 Veliparib 混悬剂的患者
-
Grupo Español de Investigación en Cáncer de Ovario完全的
-
National Cancer Institute (NCI)完全的
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation Trust未知
-
Tesaro, Inc.撤销
-
AstraZenecaKuDOS Pharmaceuticals Limited完全的
-
Ibrahim Halil SahinGlaxoSmithKline尚未招聘
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.招聘中
-
H. Lee Moffitt Cancer Center and Research InstituteGlaxoSmithKline招聘中
-
VA Office of Research and Development招聘中转移性去势抵抗性前列腺癌 | BARD1、BRCA1、BRCA2、BRIP1、CHEK1、芳珂、PALB2 | RAD51B、RAD51C、RAD51D 或 RAD54L 突变美国
-
K-Group, Beta, Inc., a wholly owned subsidiary...主动,不招人
-
Brown UniversityBayer; The Miriam Hospital; Rhode Island Hospital; Clovis Oncology, Inc.主动,不招人
-
University of Alabama at Birmingham撤销
-
Geoffrey Shapiro, MD, PhDEli Lilly and Company; AstraZeneca完全的